C10584: Novel Diagnostics for IBDNovelty:
This technology involves use of novel E. coli proteome chip to diagnose, monitor and select appropriate treatments for patients suffering from inflammatory bowel disease (IBD).
Value Proposition:
Current diagnostic methods for inflammatory bowel disease are invasive and patients find these tests unpleasant. The disclosed technology improves patient compliance, diagnostic accuracy, and early and appropriate treatment selection for IBD. The features of this invention are:
• A microchip containing a set of biomarkers for diagnosing and distinguishing Crohn’s disease and ulcerative colitis.
• Serological diagnostic procedure which is non-invasive, inexpensive, and easily tracked over treatment time.
• Data based upon confirmed patient populations.
• Allows for significantly earlier diagnosis, reducing suffering and economic cost.
Technical Details:
Johns Hopkins researchers have devised a novel high-throughput proteomic approach to screen and identify new serological biomarkers for IBD. Specifically, they used whole E. coli proteome microarray to screen Specific anti-microbial antibodies present in the sera of patients with inflammatory bowel disease (IBD) and identified a total of 417 E. coli proteins that were differentially recognized by serum antibodies between healthy controls and Crohn’s disease (CD) and ulcerative colitis (UC). Among those, 169 proteins were identified as highly immunogenic in healthy controls, 186 proteins are highly immunogenic in CD, only 19 in UC. Using a supervised learning algorithm (k-Top Scoring Pairs), the researchers identified two sets of serum antibodies that were novel biomarkers for specifically distinguishing CD from healthy controls, and CD from UC, respectively.
Looking for Partners:
To develop and commercialize the technology as an efficient diagnostic tool in treatment of Inflammatory bowel disease.
Stage of Development:
Pre-Clinical
Data Availability:
Under NDA/CDA
